Tag Archives: Onglyza

April, 2015

  • 14 April

    FDA Panel Recommends Adding Heart Failure Risk on Onglyza Label

    An advisory panel to US health regulators voted that AstraZeneca’s diabetes drug Onglyza should include new safety information about the risk of heart failure. An advisory panel to the US Food and Drug Administration (FDA) met Tuesday to review data from a large scale cardiovascular (CV) outcomes trial that assessed …

  • 10 April

    FDA Says AstraZeneca’s Onglyza May Increase Death Risk

    The US Food and Drug Administration (FDA) staff reviewers have raised serious concerns of safety issues associated with AstraZeneca’s diabetes drug Onglyza. The agency’s concerns come a few days ahead of a committee meeting to discuss the safety of DPP-4 inhibitors. The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee is …